Patents Assigned to GLG Pharma, LLC
  • STAT3 inhibitor formulation
    Patent number: 10913709
    Abstract: Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: February 9, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GLG Pharma, LLC, MRIGlobal
    Inventors: Robert H. Shoemaker, Michael W. Lovell, Jonathan M. White, Shanker Gupta
  • STAT3 INHIBITOR FORMULATION
    Publication number: 20200109109
    Abstract: Disclosed is a salt prepared from the STAT3 inhibitor known as 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino] benzoic acid and 2-amino-2-(hydroxymethyl)-1,3-propanediol. The salt is soluble in water and stable for extended periods of time. Further provided are pharmaceutical compositions comprising the salt and methods of administering the salt to prevent and treat cancer, such as breast cancer.
    Type: Application
    Filed: April 5, 2018
    Publication date: April 9, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, GLG Pharma, LLC, MRIGlobal
    Inventors: Robert H. Shoemaker, Michael W. Lovell, Jonathan M. White, Shanker Gupta